BIOINTRON Profile

We specialize in antibody production and discovery – dedicating ourselves to advancing human health and promoting sustainability with more than 10 years of experience. We offer premium solutions at competitive rates, all anchored in our commitment to a brighter and healthier future.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, optimization, and expression services for global biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression industry. From gene sequence to purified antibodies, it only takes 2 weeks. We have delivered over ten thousand of recombinant antibodies for more than 1,500 biotech and pharma companies worldwide.

We provide a one-stop solution for antibody discovery and optimization – including VHH antibody discovery, single B-cell antibody screening, hybridoma sequencing, antibody humanization, antibody affinity maturation, and more.

Additionally, Biointron holds global sublicensing rights for ECACC's CHO-K1. Our CHOK1BN cell line, which is derived from CHOK1, has been filed in the DMF system with the US FDA. By choosing the CHOK1BN cell line, several partners’ projects have entered the multicenter international clinical trials successfully.